医療診断における世界のAI市場は、2020年の5億ドルから2030年までに199.6億ドルを超え、今後数年間、つまり2021〜30年のCAGRは44.58％と予想されます。
これまでの医学における最も重要な科学的進歩の1つは、医療における人工知能です。このセクターの成長に貢献する重要な要素は、AI主導のイメージングおよび診断製品の開発に多数の新興企業が関与していることです。画像のキャプチャ、処理、報告支援、フォローアップ、データストレージ、データマイニング、およびその他の人工知能アプリケーションがすべて利用可能です。機械学習は、コンピューターモデルとアルゴリズムを人工神経網とブレンドして、脳の有機ニューラルネットワークアーキテクチャ（ANN）を模倣します。ディープラーニングは、出力の点で従来の機械学習よりも成功率が高くなります。
目次
Contents
1. Executive Summary
2. Global AI in Medical Diagnostics Market
2.1. Product Overview
2.2. Market Definition
2.3. Segmentation
2.4. Assumptions and Acronyms
3. Research Methodology
3.1. Research Objectives
3.2. Primary Research
3.3. Secondary Research
3.4. Forecast Model
3.5. Market Size Estimation
4. Average Pricing Analysis
5. Macro-Economic Indicators
6. Market Dynamics
6.1. Growth Drivers
6.2. Restraints
6.3. Opportunity
6.4. Trends
7. Correlation & Regression Analysis
7.1. Correlation Matrix
7.2. Regression Matrix
8. Recent Development, Policies & Regulatory Landscape
9. Risk Analysis
9.1. Demand Risk Analysis
9.2. Supply Risk Analysis
10. Global AI in Medical Diagnostics Market Analysis
10.1. Porters Five Forces
10.1.1. Threat of New Entrants
10.1.2. Bargaining Power of Suppliers
10.1.3. Threat of Substitutes
10.1.4. Rivalry
10.2. PEST Analysis
10.2.1. Political
10.2.2. Economic
10.2.3. Social
10.2.4. Technological
11. Global AI in Medical Diagnostics Market
11.1. Market Size & forecast, 2020A-2030F
11.1.1. By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
11.1.2. By Volume (Million Units) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12. Global AI in Medical Diagnostics Market: Market Segmentation
12.1. By Regions
12.1.1. North America:(U.S. and Canada), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.2. Europe: (Germany, UK, France, Italy, Spain, and Rest of Europe), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.3. Asia-Pacific: (China, India, Japan, Australia and Rest of Asia Pacific), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.4. Latin America: (Brazil, Mexico, Rest of Latin America), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.5. Middle East and Africa, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2. By Component: Market Share (2020-2030F)
12.2.1. Software, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2.2. Service, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3. By Application: Market Share (2020-2030F)
12.3.1. In Vivo Diagnostics, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.2. In-Vitro Diagnostics, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.4. By End-User: Market Share (2020-2030F)
12.4.1. Hospitals, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.4.2. Diagnostic imaging centers, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.4.3. Diagnostic Laboratories, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.4.4. Others, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
13. Company Profile
13.1. Microsoft Corporation
13.1.1. Company Overview
13.1.2. Company Total Revenue (Financials)
13.1.3. Market Potential
13.1.4. Global Presence
13.1.5. Key Performance Indicators
13.1.6. SWOT Analysis
13.1.7. Product Launch
13.2. NVIDIA
13.3. IBM
13.4. Intel
13.5. Siemens Healthineers
13.6. GE Healthcare
13.7. Digital Diagnostics
13.8. Xilinx
13.9. InformAI
13.10. Enlitic
13.11. Day Zero Diagnostics
13.12. Aidence
13.13. Butterfly Network, Inc.
13.14. Prognos
13.15. Zebra Medical Vision
Consultant Recommendation
**The above-given segmentations and companies could be subjected to further modification based on in-depth feasibility studies conducted for the final deliverable.
